scox – New data detail discovery and engineering of hypercompact transcriptional activation domains with greater magnitude and duration of effect than any previously described – – Epic Bio is advancing a pipeline of therapies to precisely modulate gene expression to address previously intractable diseases – SOUTH SAN FRANCISCO, Calif. — March 14, 2023 — Epic Bio, a leading … Read more
SOUTH SAN FRANCISCO, Calif. — March 6, 2023 — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced presentations at two upcoming scientific and medical conferences. Keystone Symposia: Chromatin Architecture in Development and Human HealthPoster Title: Discovery and engineering of hypercompact transcriptional modulatorsfor robust and durable … Read more
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–EPIC BIO, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced that Amber Salzman, Ph.D., chief executive officer of Epic Bio, was selected as one of 20 influential women in biopharma by Endpoints News. She will additionally be featured in Endpoints’ Women in Biopharma 2022 special … Read more
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022. Amber Salzman, Ph.D., chief executive officer, and Dan Hart, Ph.D., head of technology development, are … Read more
– New activator in the GEMS (Gene Expression Modulation System) Platform addresses limitations of existing therapy modalities –– Persistent activation of genes may provide permanent cure for diseases such as haploinsufficient diseases –– Tunable protein expression mitigates the risk of toxic overexpression – SOUTH SAN FRANCISCO, Calif. — October 31, 2022 — Epic Bio, a biotechnology company … Read more
SOUTH SAN FRANCISCO, Calif. — October 24, 2022 — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced its participation at the 6th International Conference on Epigenetics and Bioengineering, held in Houston, Texas, taking place October 27 – 29, 2022. ICEB 2022 Presentation Details: Poster Presentation Title: GEMS: … Read more
SOUTH SAN FRANCISCO, Calif. – October 13, 2022 – Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced a presentation on the company’s unique engineering platform, called the Gene Expression Modulation System (GEMS), at the co-hosted Solebury / BMO Fall Private Company Showcase. “We are excited … Read more
SOUTH SAN FRANCISCO, Calif. — October 6, 2022 — EPIC BIO, a biotechnology company developing therapies to modulate gene expression using the compact, non-cutting dCas protein, today announced that the company will be participating in the Solebury / BMO Fall Private Company Showcase, taking place Thursday, October 13, 2022, in New York. The event is co-hosted by … Read more